Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VICL (Vical Labs) -- Ignore unavailable to you. Want to Upgrade?

To: William Strop who wrote (1179)	12/28/1999 11:37:00 PM
From: Scott H. Davis	Read Replies (1) \| Respond to of 1972

Seeing several things, a strong biotech/healthcare day with strong institutional accumulation (look at the healthcare industry group & biotech sector), thomsoninvest.net thomsoninvest.net the likelyhood of continued progress on malaria, the Allovectin news, with the implications of the PIII on patients who had not had prior chemo (in my opinion/hope?) means a good shot a first line therapy approval if successfull So perhaps it's a collective judgement that VICL has made enough progress on multiple fronts that the risk/reward picture is better. One thing for sure, if they can sell 2.5 m shares at near these prices, with their burn management and periodic licensing deals & milestones, looks like they have enough cash to complete some projects. Not seeing any analyst upgrades/new coverage tho. IMSCO Scott